Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms
| Authors | |
|---|---|
| Year of publication | 2016 |
| Type | Article in Periodical |
| Magazine / Source | Blood |
| MU Faculty or unit | |
| Citation | MILOSEVIC FEENSTRA, Jelena; Harini NIVARTHI; Heinz GISSLINGER; Emilie LEROY; Elisa RUMI; Ilyas CHACHOUA; Klaudia BAGIENSKI; Blanka KUBEŠOVÁ; Daniela PIETRA; Bettina GISSLINGER; Chiara MILANESI; Roland JÄGER; Doris CHEN; Tiina BERG; Martin SCHALLING; Michael SCHUSTER; Christoph BOCK; Stefan N. CONSTANTINESCU; Mario CAZZOLA and Robert KRALOVICS. Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms. Blood. Washington: American Society of Hematology, 2016, vol. 127, No 3, p. 325-332. ISSN 0006-4971. Available from: https://doi.org/10.1182/blood-2015-07-661835. |
| Doi | https://doi.org/10.1182/blood-2015-07-661835 |
| Field | Oncology and hematology |
| Keywords | MPL; JAK2; neoplasms; mutations; myeloproliferative neoplasms |
| Description | Essential thrombocythemia (ET) and primary myelofibrosis (PMF) are chronic diseases characterized by clonal hematopoiesis and hyperproliferation of terminally differentiated myeloid cells. The disease is driven by somatic mutations in exon 9 of CALR or exon 10 of MPL or JAK2-V617F in > 90% of the cases, whereas the remaining cases are termed "triple negative." We aimed to identify the disease-causing mutations in the triple-negative cases of ET and PMF by applying whole-exome sequencing (WES) on paired tumor and controlsamples from 8 patients. We found evidence of clonal hematopoiesis in 5 of 8 studied cases based on clonality analysis and presence of somatic genetic aberrations. WES identified somatic mutations in 3 of 8 cases. We did not detect any novel recurrent somatic mutations. In 3 patients with clonal hematopoiesis analyzed by WES, we identified a somatic MPL-S204P, a germline MPL-V285E mutation, and a germline JAK2-G571S variant. We performed Sanger sequencing of the entire coding region of MPL in 62, and of JAK2 in 49 additional triple-negative cases of ET or PMF. New somatic (T119I, S204F, E230G, Y591D) and 1germline(R321W) MPL mutation were detected. All of the identified MPL mutations were gain-of-function when analyzed in functional assays. JAK2 variants were identified in 5 of 57 triple-negative cases analyzed by WES and Sanger sequencing combined. We could demonstrate that JAK2-V625F and JAK2-F556V are gain-of-function mutations. Our results suggest that triple-negative cases of ET and PMF do not represent a homogenous disease entity. Cases with polyclonal hematopoiesis might represent hereditary disorders. |
| Related projects: |